Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for Vitreous Hemorrhage in PDR
NCT01824043Phase 4Unknown
- Sponsor
- Hospital Regional de São José - Dr. Homero de Miranda Gomes
- Start
- Mar 2013
- Primary completion
- Sep 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in proliferative diabetic retinopathy (PDR) and Vitreous hemorrhage (VH), sponsored by Hospital Regional de São José - Dr. Homero de Miranda Gomes. Primary endpoint: Gain in visual acuity and transparence of vitreous in treated eyes at 90 days. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)Vitreous hemorrhage (VH)
Beyond the preview
Go deeper on NCT01824043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824043.